Vivozon Pharmaceutical said on the 23rd that the non-opioid analgesic "Onapra injection (hereafter Onapra)" reached 2.87 billion won in sales just two months after launch. This exceeds the guidance the company presented at launch.
Onapra is a first-in-class innovative new drug that received sales approval from the Ministery of Food and Drug Safety last year. Full-scale supply to domestic medical institutions began on Oct. 30.
The company said, "Approvals by the pharmacy and therapeutics committees (DC) of major large general hospitals with strong demand are proceeding smoothly," adding, "We have currently completed approvals at 16 university hospitals."
Vivozon Pharmaceutical projected that Onapra's sales will increase rapidly starting next year. The company said it has also secured capacity to respond to expanded sales, as additional volumes produced by a Chinese global contract manufacturing organization (CMO) pharmaceutical company are scheduled to be introduced in the first quarter next year.
A Vivozon Pharmaceutical official said, "Although Onapra is in the early stage of release, the market response is emerging faster than expected," adding, "It has proven Vivozon's commercialization capabilities to the market." The official added, "Taking the successful establishment of Onapra in the domestic market as a starting point, we will work with affiliate Vivozon to prepare for U.S. clinical trials and expand our entry into the global market."